Pioneering sepsis treatment
Sangair has developed a unique technology to support treatment of patients during sepsis.
In 2015, Johan Sjöholm and Professor Lennart Ljunggren came up with the invention to treat blood of sepsis patients through a method that combines prior art with new discoveries.
They had previously discovered that Escherichia coli (E. coli) microorganisms could be killed using active oxygen without causing adverse effects on proteins and fats.
In 2016, Sangair was founded, and the first animal trials were conducted in Lund in August of the same year. Today, Sangair is conducting pre-clinical studies on E. coli-contaminated animals, along with more in-depth in vitro studies following new regulations. The plan is to carry out clinical studies in the next couple of years and subsequently apply for CE certification.
The system and its process are patented
The Board
Niclas Jonasson
Chairman of the Board
Niclas has a long and broad international experience from senior positions within the medical device and life science industry.
Johan Sjöholm
Board-member, Founder
Johan Sjöholm is the founder of Sangair. Johan has a long experience as entrepreneur and has taken several products to the market.
Martin Wiklund
Board member
Martin Wiklund holds university degrees in both business administration and medical science. Martin has founded and developed one of Southern Sweden’s largest and privately owned health care centres.
Henrik Rundgren
Board member
Being a successful, experienced business generator, Henrik has established partner networks in international environments and has a large international network.
